Standard BioTools (FLB) Stock Statistics & Valuation Metrics

Standard BioTools has a market cap or net worth of CHF296.74M. The enterprise value is $79.96M.

Standard BioTools has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Standard BioTools’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -12.21%.

The current PE Ratio of Standard BioTools is ―. Standard BioTools’s PEG ratio is 0.10.

In the last 12 months, Standard BioTools had revenue of 85.33M and earned -74.90M in profits. Earnings per share was -0.20.

In the last 12 months, operating cash flow was -90.66M and capital expenditures -3.82M, giving a free cash flow of -94.48M billion.

Standard BioTools pays an annual dividend of ―, resulting in a dividend yield of ―

Standard BioTools upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Standard BioTools as a current ratio of 4.19, with Debt / Equity ratio of 5.26%

In the past 12 months, Standard BioTools has paid -37.88M in taxes.

Standard BioTools EV to EBITDA ratio is -4.47, with an EV/FCF ratio of -4.85.

Standard BioTools has CHF455.18M in cash and marketable securities with CHF29.49M in debt, giving a net cash position of CHF425.69M billion.

Gross margin is 48.30%, with operating margin of -109.34%, and net profit margin of -87.77%.

The average price target for Standard BioTools is CHF1.09, which is 11.43% higher than the current price. The consensus rating is Hold